Dr. Steven E. Finkelstein spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “Novel Radiopharmaceuticals for Prostate Cancer.”

 

Keywords: novel radiopharmaceuticals, prostate cancer[/su_tab]

How to cite: Finkelstein, Steven E. “Novel Radiopharmaceuticals for Prostate Cancer ” Grand Rounds in Urology. August 7, 2015. Accessed Apr 2024. https://grandroundsinurology.com/prostate-cancer-steven-e-finkelstein-novel-radiopharmaceuticals-for-prostate-cancer/.

References

Bruland ØS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s.
http://www.ncbi.nlm.nih.gov/pubmed/17062709

Henriksen G, Breistøl K, Bruland ØS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002 Jun 1;62(11):3120-5.
http://www.ncbi.nlm.nih.gov/pubmed/12036923

Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008 Sep;38(5):358-66.
http://www.ncbi.nlm.nih.gov/pubmed/18662557

McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998 Sep;25(9):1341-51.
http://www.ncbi.nlm.nih.gov/pubmed/9724387

Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94.
http://www.ncbi.nlm.nih.gov/pubmed/17544845

Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977 Apr 14;266(5603):653-5.
http://www.ncbi.nlm.nih.gov/pubmed/859634

Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36.
http://www.ncbi.nlm.nih.gov/pubmed/21685461

Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012 Sep;30(5):607-13.
http://www.ncbi.nlm.nih.gov/pubmed/20888271